Phenibut

Russian Rx anxiolytic (1960s, Perekalin lab, Leningrad) marketed in the West as a benign "supplement" that, in reality, is a long-acting GABA-B agonist + gabapentinoid with brutal physical dependence — ICU-grade withdrawal in 44% of documented cases, 24% intubated, 8% seizures (2024 systematic review). Tolerance builds within days at recreational doses. SKIP-PERMANENT for every archetype. No biohacker use case justifies the dependence pharmacology. Selank covers the anxiolytic niche without the dependence trap.

Phenibut is β-phenyl-γ-aminobutyric acid — a GABA molecule with a phenyl ring substituted at the β-carbon. The phenyl group does one critical thing: it raises lipophilicity enough for the molecule to cross the blood-brain barrier (free GABA does not penetrate the BBB meaningfully).

Once in the CNS, phenibut acts at two distinct targets:

1. GABA-B receptor full agonist. Same target as baclofen, GHB/GBL, and the body's endogenous GABA. GABA-B activation hyperpolarizes neurons via Gi/Go-coupled K⁺ channel opening and Ca²⁺ channel inhibition, producing anxiolysis, sedation, muscle relaxation, and at higher doses euphoria + hypnosis. Phenibut is roughly 30-50× weaker than baclofen at this receptor, which is the pharmacological reason therapeutic Russian doses are 250-500 mg (vs. baclofen's 5-20 mg) and recreational doses run 1-3 g.

2. α2δ-1 subunit of voltage-gated calcium channels (VGCCs). This was only recognized in 2015 — phenibut is, mechanistically, a gabapentinoid, the same class as gabapentin and pregabalin. Its KD at α2δ is ~21 µM vs. gabapentin's ~0.05 µM (i.e., gabapentin binds ~400× tighter), so phenibut's gabapentinoid arm is mechanistically real but secondary to the GABA-B arm at clinically encountered concentrations. The α2δ binding contributes to its anti-seizure profile, anti-anxiety effect at moderate doses, and likely to the cross-tolerance pattern with gabapentin/pregabalin observed in case literature.

3. Minor effects: weak dopaminergic activity (some users describe a low-dose "social stimulation" tier reminiscent of low-dose alcohol or low-dose GHB — this is not a robust pharmacological effect at therapeutic doses) + β-phenethylamine (PEA) antagonism (contributes to anxiolysis, since endogenous PEA is mildly anxiogenic).

Plain English: Phenibut is a GABA molecule wearing a phenyl-ring "hat" so it can sneak into the brain. Inside, it does what your endogenous GABA does — calms neurons — but it does it longer (5.3 hr half-life) and at the same receptor that benzodiazepines, alcohol, GHB, and baclofen target (different sub-receptors but overlapping inhibitory cascade). Stop taking it after a few weeks of daily dosing and your nervous system, which has down-regulated to compensate, is suddenly under-inhibited — that's the autonomic crisis, the seizures, and the delirium.

Key pharmacokinetic facts:

• Half-life: ~5.3 hours (single 250 mg dose, healthy volunteers)
• Onset: 1.5-3 hours oral (slow — recreational users often re-dose, escalating exposure)
• Peak: 3-4 hours
• Total duration: 10-16 hours
• Excretion: ~63% urinary, unchanged
• No bioaccumulation reported at therapeutic doses, but tolerance dynamics dominate — drug clearance is not the limiting factor for safety, neuroadaptation is.
• Detection: Standard immunoassay drug screens do NOT detect phenibut. LC-MS is required. This is why ED clinicians frequently miss the diagnosis.